The primary cause of mortality for glioblastoma (GBM) is local tumor recurrence following standard-of-care therapies, including surgical resection. With most tumors recurring near the site of surgical resection, local delivery of chemotherapy at the time of surgery is a promising strategy. Herein drug loaded polymer scaffolds with two distinct degradation profiles were fabricated to investigate the effect of local drug delivery rate on GBM recurrence following surgical resection. The novel biopolymer, acetalated dextran (Ace-DEX), was compared to commercially available polyester, poly(L-lactide) (PLA). Steady state doxorubicin (DXR) release from Ace-DEX scaffolds was found to be faster when compared to scaffolds comprised of PLA, in vitro. This increased drug release rate translated to improved therapeutic outcomes in a novel surgical model of orthotopic glioblastoma resection and recurrence. Mice treated with DXR loaded Ace-DEX scaffolds (Ace-DEX/10DXR) resulted in 57% long term survival out to study completion at 120 days compared to 20% survival following treatment with DXR loaded PLA scaffolds (PLA/10DXR). Additionally, all mice treated with PLA/10DXR scaffolds exhibited disease progression by day 38, as defined by a five-fold growth in tumor bioluminescent signal. In contrast, 57% of mice treated with Ace-DEX/10DXR scaffolds displayed a reduction in tumor burden, with 43% exhibiting complete remission. These results underscore the importance of polymer choice and drug release rate when evaluating local drug delivery strategies to improve prognosis for GBM patients undergoing tumor resection.
INTRODUCTION
Glioblastoma (GBM) is an especially aggressive, grade IV central nervous system tumor.
GBM is the most common primary brain tumor and accounts for 45-50% of all gliomas, 1 and even with surgical resection, radiation, and chemotherapy, the median survival for GBM patients remains only 12 to 15 months. [1] [2] [3] The primary cause of mortality for GBM is local tumor recurrence, with 90 -95% of tumors recurring within 2 cm of the original tumor. [4] [5] [6] [7] As such, patient outcomes could be greatly improved by delaying or preventing local recurrence.
Unfortunately, chemotherapeutic options are limited due to the inability of most drugs to cross the blood-brain barrier. One strategy to improve drug delivery to GBM and bypass the bloodbrain barrier is interstitial chemotherapy. This can be achieved by lining the resection cavity with a material that releases drug as it degrades. 8 This strategy is applied clinically with Gliadel ® , a polyester and polyanhydride polymer wafer that is used in some GBM patients to deliver carmustine (BCNU) directly into the resection cavity. 9 Unfortunately, Gliadel ® only extends median survival by 10-18 weeks over placebo. 10, 11 This is likely due to the low tumoricidal activity of BCNU against GBM and its rapid clearance from the brain after release from the polymer wafer. [12] [13] [14] Additionally, tumor cells easily acquire resistance to alkylating agents like 4 BCNU through the DNA repair mediated by the enzyme O 6 -methylguanine-DNA methyltransferase (MGMT). 15, 16 Low tumoricidal activity, easily acquired drug resistance, and rapid clearance of BCNU from the brain highlight the need for exploration into alternative anticancer drugs for interstitial therapy.
One promising compound to combat GBM is doxorubicin (DXR). This highly potent chemotherapeutic agent induces cell death via multiple mechanisms of action, including DNA intercalation and interaction with topoisomerase II. 17, 18 However, DXR is unable to be administered systemically against GBM due to its inability to pass through the blood-brain barrier and reach therapeutic levels in the brain. 19 Interstitial delivery of DXR against GBM has been explored previously with some success. Local delivery of DXR was able to extend median survival and delay tumor growth, but ultimately complete remission was not achieved. 20, 21 This is likely due to the sub-optimal DXR release kinetics from the polymeric devices utilized for interstitial therapy. Lesniak et al. has shown that interstitial DXR delivered via a polyanhydride polymer wafer was able to extend median survival of Fisher rats with intracranial glioma from 21 to 45 days, despite the fact that DXR release from the polymer wafer plateaued at approximately 14% after the first 50 hours. 20 Lin et al. also found that DXR released from polyester polymer device was able to slow tumor growth in a subcutaneous flank model. 21 Similar to the polyanhydride wafers, the polyester device displayed an initial release of DXR that plateaued after the first 2 days. This pattern of stagnant DXR release after an initial period of rapid release over the first few days is also seen in multiple polymer drug delivery platforms including polyanhydrides, 20 polyesters, 21, 22 and polyethylene glycol polyester composites. 23, 24 The therapeutic efficacy of interstitial GBM treatment could be greatly improved with sustained DXR release from an optimal polymer matrix.
Aggressive cancers, such as GBM, recur in a matter of weeks. As such, polymer drug delivery platforms capable of rapid and sustained drug release are vital to suppressing local tumor recurrence. Most commonly used polymers for interstitial drug delivery, such as polyesters and polyanhydrides, have relatively slow degradation rates on the order of months to years. 25, 26 Additionally, polyesters degrade by bulk degradation, which can lead to spontaneous dumping of drug and potential unforeseen toxicity. 27 An example of this can be seen in Manome et al., where poly(D,L-lactide-co-glycolide) (PLGA) sheets exhibited a sudden burst release of DXR around 30 days in vitro. Finally, polyesters create an acidic microenvironment as they degrade, which can alter drug activity and cause tissue toxicity. [28] [29] [30] Taken together, these limitations regarding effective drug release and adverse polymer by-products highlight the need for a tunable drug delivery platform to expand the population of drugs that can be utilized for sustained interstitial drug delivery.
An alternative polymer for drug delivery is acetalated dextran (Ace-DEX). Ace-DEX is a novel polymer with tunable degradation rates ranging from days to months. It is synthesized by chemically modifying dextran with 2-ethyoxypropene to render the polymer hydrophobic. 31, 32 This reaction generates acyclic and cyclic acetals on the pendent hydroxyl groups of dextran in a time-dependent manner. [33] [34] [35] The ratio between cyclic and acyclic acetals can be changed based on the length of reaction time. [33] [34] [35] Under aqueous conditions, acetal groups are hydrolyzed, revealing the parent hydroxyl groups of dextran and resulting in Ace-DEX degradation. Since cyclic acetals are significantly more stable to hydrolysis than acyclic acetals, the time-dependent nature of acetal coverage allows for tight control of Ace-DEX degradation rate. The degradation by-products of Ace-DEX (dextran, acetone, and ethanol) are pH neutral and occur at exceedingly low concentrations, far below levels that would result in toxicity. 33, 34 Our group has previously 6 fabricated drug loaded Ace-DEX nanofibrous scaffolds using electrospinning, and demonstrated tunable drug release and bioactivity. 31 The tunability of Ace-DEX degradation rates combined with the safe, pH-neutral degradation products makes it a promising polymer platform for interstitial drug delivery against GBM. To advance this potential therapy towards translation to the clinic, it is imperative that we evaluate GBM treatment in the most relevant animal model.
The therapeutic efficacy of interstitial therapy against GBM is often tested in a simple subcutaneous flank or orthotopic tumors that fail to incorporate an essential component of multimodal therapy: surgical resection. As surgery is the standard of care for human patients, a preclinical animal model of GBM resection and recurrence is extremely beneficial. This is particularly important because surgical resection induces changes in the peri-tumoral microenvironment and influences tumor biology, growth, and invasion. 36 We previously developed a fluorescent-guided surgical mouse model of GBM resection and recurrence. 37, 38 With this model, GBM xenografts are implanted orthotopically and allowed to establish for several days. Under fluorescent guidance, approximately 90% of the tumor is removed by surgical resection and interstitial therapy can then be applied at the time of surgery (Figure 1 ).
Here we describe the fabrication and utilization of electrospun DXR loaded polymer scaffolds comprised of Ace-DEX or poly(L-lactide) (PLA), a polyester commonly used for interstitial drug delivery. We then investigated the effect of polymer on DXR release from scaffolds in vitro.
DXR release rates were then evaluated in a clinically relevant murine model of local GBM recurrence following partial surgical resection. 
EXPERIMENTAL METHODS

Chemicals and Reagents
Dextran (molecular weight 450-650 kDa), anhydrous dimethyl sulfoxide (DMSO, >99.9%), hexafluoro-2-propanol (HFIP, >99%), 1-butanol, triethylamine (TEA, >99%), pyridinium ptoluenesulfonate (>98%), poly-L-lactide (PLA, molecular weight 260 kDa), thiazolyl blue tetrazolium bromide (MTT), and BCNU (99%) were purchased from Sigma (St. Louis, MO).
Doxorubicin hydrochloride (DXR, >99%) was acquired from LCLabs (Boston, MA). 2-ethoxypropene was purchased from Matrix Scientific (Columbia, SC). High glucose Dulbecco's Modified Eagle Medium (DMEM) cell culture medium and fetal bovine serum were obtained 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 hours, before the reaction was quenched with TEA. Ace-DEX was precipitated in basic water and lyophilized. Afterwards, the polymer was dissolved in ethanol and centrifuged to remove impurities. Ace-DEX was then re-precipitated in basic water, lyophilized, and stored at -20˚C until it was used. The relative extent of cyclic acetal coverage, which dictates the degradation rate of the polymer, was calculated via nuclear magnetic resonance (NMR, Varian Inova 400) based on a previously developed method.
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Scaffold fabrication
Ace-DEX or PLA was dissolved in organic solvents at 200 mg/mL with 5% or 10% (wt/wt) DXR and loaded into a glass syringe with a blunt 21 gauge needle. A bias of 20 kV (−10 kV to the collection surface and +10 kV to the needle) was applied over a 13 cm working distance at a butanol.
Scaffold characterization
Scanning electron microscopy was performed to assess the morphology of the electrospun scaffolds. Scaffolds were mounted on aluminum stubs using carbon tape, and imaged at 2 kV on Hitachi S-4700 Cold Cathode Field Emission Scanning Electron Microscope. DXR encapsulation efficiency was defined as the ratio of empirical DXR loaded to theoretical loading.
To quantify this, scaffold samples were weighed, dissolved in DMSO, and evaluated by optical absorption at 480 nm. The amount of DXR loaded was then determined by calibration curve. To evaluate DXR release in vitro, approximately 1 mg of scaffold was placed into dialysis cups with a molecular weight cutoff of 7 kDa and added to a sink of phosphate buffered saline (PBS, pH 7.4) stirring at 37°C. At predetermined time points, scaffolds were removed and stored at -20°C.
Samples were then lyophilized, dissolved in DMSO, and evaluated by optical absorption at 480
nm. The amount of DXR retained in each sample was determined by a calibration curve.
Animals
Nude BALB/c mice were housed in groups of five in a vivarium maintained on a 12 hour light/dark schedule at 30°C and 50% relative humidity. Food and water were available ad libitum. For all surgical procedures, mice were anesthetized by vapor isoflurane and immobilized on a three point stereotactic frame (Stoelting, Kiel, WA). For all surgeries, subcutaneous carpofen (5 mg/kg) was administered prior to surgery and twice daily for 3 days following surgery for pain management. Tissue Adhesive (3M, Maplewood, MN). Several days after cranial windows were established, the dura over the cranial window was cut away, and a section of the right frontal lobe was removed by aspiration creating a pseudo resection cavity approximately 1 to 2 mm deep. DXR loaded Ace-DEX scaffolds were placed in the resection cavity and the skin was closed with tissue adhesive. Mice were evaluated daily for two weeks to assess for gross toxicity as evidenced by weight loss or gait abnormalities. After 14 days, mice were euthanized by cardiac perfusion. Brains were extracted and fixed in formalin in preparation for histology.
Therapeutic efficacy against recurrent GBM
The therapeutic efficacy of drug loaded scaffolds against local GBM recurrence was evaluated in an image-guided surgical model of GBM resection and recurrence as described previously has been shown to affect tumor xenografts and drug sensitivity in nude mice. 40 Excluded mice Figure S1 , Table. Mice were evaluated daily and euthanized if they lost more than 15% body weight. The study was conducted for 120 days. After euthanasia by cardiac perfusion, the brain was extracted, formalin fixed and paraffin embedded, and saved for histological evaluation.
Statistical Analysis
Statistical analysis of normalized mouse weights after scaffold implantation was performed by two way analysis of variance with post-hoc Bonferroni test using GraphPad Prism (La Jolla, CA).
Statistical analysis of overall and progression free survival rates was performed by proportional hazards regression with adjustment for the initial tumor size after surgical resection using IBM SPSS Statistics 24 (Chicago, IL). Scaffold fabrication and characterization Drug-eluting polymer scaffolds were fabricated by electrospinning. The organic solvent system and drug loading were varied to determine their respective role in DXR release. First, Ace-DEX scaffolds containing a fixed loading of 5% (wt/wt) DXR (Ace-DEX/5DXR) were electrospun varying the solvent system ratio of HFIP to butanol to 90:10, 80:20, and 60:40. The solvent system affected both fiber width and burst release of DXR. Increasing the volume fraction of HFIP generated wider fibers (Figure 2a-c) , which correlated with a faster burst release of DXR (Figure 2e) , and the scaffolds exhibiting a more vibrant hue of orange, the color of DXR. The effect of DXR loading on release rate was also investigated. Figure 3a -c illustrates that increasing DXR loading from 5% to 10% (wt/wt) had no effect on fiber morphology. Increasing DXR loading did result in a higher burst release of DXR (Figure 3f) ; however, afterwards the rate of DXR release is less pronounced (data not shown). To directly compare Ace-DEX to a (Figure 3g , Table) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Treatment with Ace-DEX/10DXR scaffolds statistically improved survival rates compared to Ace-DEX/blank (p < 0.005) and 'no treatment' (p < 0.005) with four mice surviving to the end of the study (Day 120) (Figure 5a, 5b) . Of these four surviving mice, only one had BLI evidence of tumor at the end of the study. Notably, the quantified BLI for this mouse decreased to just 20% of its original signal the day after resection (Day 1) over the length of the study (120 days) (Figure 5c ). In contrast, only one mouse treated with PLA/10DXR survived to the end of the study, and over this time, the tumor BLI signal increased by more than eight fold (Figure 5b,   5c ). Treatment with PLA/10DXR scaffolds statistically improved overall survival rates compared to 'no treatment' control group (p < 0.05), but was not significant compared to PLA/blank (Figure 5a ). Tumor recurrence occurred for all mice in the 'no treatment' control group. As expected, unloaded polymer scaffolds, Ace-DEX/blank and PLA/blank, had no effect on GBM recurrence compared to 'no treatment' controls. U87-MG tumors regrew at exponential rates for all control mice. BLI measurements throughout the study for each mouse can be found in Supporting Information Figure S5 .
Histology
Efficacy against recurrent GBM
Non-invasive imaging with BLI offered the opportunity to track tumor growth in real time. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 BCNU. This illustrates that DXR is highly potent against GBM and could be an enormously beneficial option for GBM patients. However, because systemic treatment with DXR is associated with severe peripheral toxicity, including irreversible cardiotoxicity, combined with the inability of DXR to cross the blood-brain barrier at therapeutic levels, DXR remains an untapped potential for GBM therapy. 19, 43 Electrospinning and scaffold characterization
We next fabricated drug-eluting polymer scaffolds for interstitial DXR therapy. Scaffolds were fabricated by electrospinning, a technique that generates a thin, flexible, fibrous scaffold which is ideal for implantation in the brain. 31 Scaffold flexibility allows the implant to contour to the shape of the resection cavity, maximizing contact surface area, while the thin nature of the scaffold reduces the risk of mass effects. This is in contrast to Gliadel ® , which is a hard disk that cannot easily cover contoured surfaces. Importantly, electrospinning is an inexpensive and scalable technique that can be used to control drug delivery kinetics by varying parameters such as solvent system, drug loading, and polymer platform. These variables were separately investigated to determine their role in DXR release.
To ensure sustained DXR release over an extended period of time, a slowly degrading Ace-DEX polymer with 60% relative cyclic acetal coverage was utilized for scaffold generation.
First, the organic solvent system and drug loading was varied to determine their respective 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 effects on DXR release from Ace-DEX. Varying the organic solvent system affected both fiber width and burst release of DXR. Increased volume fractions of HFIP generated wider fibers, a faster burst release of DXR, and brighter orange scaffolds. These effects are likely from two separate phenomena. The increase in fiber diameter is likely due to the higher volatility of HFIP, leading to more rapid solvent evaporation. The increase in burst release is likely dependent on drug and solvent system compatibility and indicates that DXR is concentrated at the surface of the fiber rather than well distributed throughout. 22, 44 This is confirmed visually, as scaffolds with higher burst releases were a more vibrant hue of orange, the color of DXR. Increasing DXR loading from 5% to 10% weight loading led to a higher burst release, likely due to the hydrophilicity of DXR. Since high DXR burst release reduces the overall drug reservoir for controlled and sustained release, the solvent system with a lower volume fraction of HFIP, 60%
HFIP and 40% butanol, was used for the remainder of the studies.
Polyesters are one of the most commonly used polymers for drug delivery, 21, 22, 45-52 however their slow degradation rates can be a limiting factor for effective drug delivery. To investigate the role that polymer platform has on DXR release a scaffold composed of PLA was fabricated under identical electrospinning conditions to Ace-DEX. Controlling for fabrication parameters (polymer concentration, DXR loading, solvent system, and flow rate) allows for a direct comparison between Ace-DEX and PLA. Both scaffolds had nearly identical morphologies as visualized by electron microscopy, however, the release rate of DXR varied quite drastically.
PLA/10DXR scaffolds were found to exhibit a high burst release followed by almost no release over the rest of the 5 week study. This is consistent with the literature, where Zeng et al. showed a rapid release of DXR from an electrospun PLA scaffold that stagnated over time. 22 By contrast, Ace-DEX/10DXR released approximately 25% as a burst release and then another 27% of DXR 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26 in a controlled manner over the remaining 5 weeks. Although the two scaffolds ultimately released similar amounts of DXR (approximately 50% over 35 days), the steady-state release from Ace-DEX scaffolds is faster than that from PLA, which releases the majority of the DXR within the first 24 hours. This differential release rate will allow investigation into the role of DXR release kinetics as determined by polymer platform in controlling GBM recurrence.
Maximum tolerated dose
Prior to testing the efficacy of DXR loaded Ace-DEX scaffolds against GBM, in vivo toxicity was evaluated. To mimic tumor treatment, cranial windows and a resection cavity approximately 3mm in diameter and 1 to 2 mm deep were created in the parenchyma of nude mice. DXR loaded Ace-DEX scaffolds were then implanted into the surgical cavity. To increase the total dose of DXR administered, the scaffold drug loading was maintained and overall mass of scaffold implanted was increased. To achieve the highest DXR dose tested (200 µg), 2.2 mg of total Ace-DEX/10DXR scaffold mass was required. Interestingly, all but the highest dose of DXR, 200 µg, was well tolerated as measured by mouse weight loss. The tolerated dose was higher than expected based on literature where Kooistra et al. found that the highest non-toxic tolerated dose of intrathecal DXR for Sprague Dawley rats was 20 µg. 53 This discrepancy may be due to the fact that the dose is not entirely contained intra-cranially (as the cranial window is left open), differences between rats and mice, and the controlled release of drug from the scaffold, compared to bolus delivery. Although by histology, dose-dependent toxicity was seen at doses as low as 100 µg, to maximize therapeutic dose within tolerable toxicity, 150 µg DXR was tested for therapeutic efficacy. Efficacy against recurrent GBM Surgical resection is part of the standard-of-care for GBM patients. However, the majority of preclinical studies are conducted in mouse or rat models that lack surgical resection of the primary tumor. 20, 45, [54] [55] [56] To mimic clinical conditions, tumor cells are implanted into the parenchyma of mice. Once tumors are well established, the established primary GBM mass is resected using fluorescent-guided microsurgery. The surgical resection greatly transforms the brain microenvironment with studies showing tumors re-grow more aggressively than the original primary tumor. 36 These findings underscore the significance of utilizing this clinically relevant mouse model for pre-clinical GBM therapies.
As expected, tumors for control mice (untreated and blank scaffolds) regrew rapidly. However, treatment with DXR loaded scaffolds composed of both Ace-DEX and PLA led statistically improved survival rates compared 'no treatment' controls. Despite the slow steady state release of DXR from PLA/10DXR scaffolds, treatment with PLA/10DXR extended median survival from 29 to 63 days over PLA/blank. However, the lack of statistical significance differs from previous reports in the literature where Lesniak et al. 20 and Lin et al. 21 found that DXR loaded polyester or polyanhydride devices were able to significantly extend median survival and delay tumor growth over empty polymer devices. Since overall and progression free survival rates of PLA/10DXR were significant when compared to the 'no treatment' control group, the low sample size of our study may be a contributing factor in the lack of statistical significance when compared to PLA/blank. Additionally, the surgical murine model used in this study is unique in its clinical significance, with more aggressive tumors recurrence than primary GBM models. The complexity of this model may have highlighted limitations with PLA delivery of DXR.
Moreover, the total therapeutic dose of DXR implanted for interstitial therapy in this work was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   28 lower than previous studies. 20, 21 This suggests that the ratio of drug to tumor size may be an important factor in interstitial therapy.
As evidences in Figure 5e , residual tumor size after resection was quite variable.
Unfortunately, because tumors do not grow homogenously and surgical conditions are not equivalent, it is difficult to ensure identical residual tumor size after resection. Although this variation is difficult in a research setting, this model closely mimics the clinical setting where incomplete or insufficient tumor resection outcomes are often a reality. In this way, the range of residual tumors at the start of treatment allows some insight into the robustness of each therapy.
Not surprisingly, residual tumor size after surgical resection played a significant role in therapeutic efficacy. For the PLA/10DXR group, mice with larger residual tumors after surgical resection succumbed to tumors faster than those with smaller residual tumors. This is likely due to the slow steady state release of DXR from PLA scaffolds which allowed tumor growth to outpace DXR release. The success of mice treated with Ace-DEX/10DXR was also dependent on residual tumor size. Mice with smaller residual tumors were more responsive to therapy than those with larger tumors. However, in contrast with PLA/10DXR, the size threshold for tumor recurrence was much higher for Ace-DEX/10DXR.
Due to this residual tumor size discrepancy, a more uniform comparison between therapies can be made by comparing representative mice with similar sized tumors after resection (highlighted in blue in Figure 5e ). In this case, PLA/10DXR resulted in an initial decrease in tumor burden, possibly due to the burst release of DXR from the scaffold; however, tumor regrowth ultimately outpaced the slow steady state DXR release from the PLA scaffold (Figure 5f ). In contrast, the release of DXR from Ace-DEX/10DXR scaffolds was high enough to result in complete remission for a residual tumor of the same size. This direct comparison helps to highlight the benefits of the higher steady state DXR release from Ace-DEX scaffolds.
CONCLUSIONS
Despite current treatments, local GBM recurrence and associated mortality is almost 100%. This is complicated by the fact that the blood-brain barrier limits efficacy of systemic chemotherapy. To combat recurrence and overcome the blood-brain barrier, local drug delivery to the tumor resection site is highly advantageous. Judicious selection of a polymer platform is essential to ensure sustained drug delivery. The most commonly used polymers for drug delivery are limited by slow degradation rates. Previous reports of polymeric delivery of DXR exhibited similar trends: rapid release of DXR over the first few days followed by slow steady state release. Although this led to improved median survival or tumor growth delays, to our knowledge no complete remissions have been achieved.
Here we addressed the need for an improved polymer platform for sustained interstitial drug delivery to prevent GBM recurrence. DXR was incorporated into nanofibrous scaffolds composed of PLA or Ace-DEX to directly compare the effect of polymer on DXR release rate.
Although both DXR loaded scaffolds ultimately release approximately the same amount of DXR, PLA/10DXR scaffolds released the full payload within the first 24 hours, whereas Ace-DEX/10DXR scaffolds exhibited controlled and sustained release of DXR over the same period.
PLA/10DXR scaffolds extended progression free survival over 'no treatment' control; however, all mice in this treatment group exhibited tumor growth by 38 days after treatment. The higher sustained DXR release from Ace-DEX scaffolds led to more robust suppression of tumor recurrence, leading to complete remission in 43% of mice. Future studies will further explore the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 30 tunability of the Ace-DEX polymer platform, to determine the optimal degradation rate to maximally suppress GBM recurrence. 
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